NCT02103426View on ClinicalTrials.gov

An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 30, 2013

Primary Completion Date

May 10, 2016

Study Completion Date

May 10, 2016

Conditions
DialysisHealthy SubjectsCytomegalovirus Infection
Interventions
DRUG

ASP0113

intramuscular injection

DRUG

Placebo

intramuscular injection

Trial Locations (4)

21225

Site US10001, Baltimore

32809

Site US10003, Orlando

77099

Site US10004, Houston

90017

Site US10009, Los Angeles

Sponsors

Collaborators (1)

Vical
All Listed Sponsors
collaborator

Vical

INDUSTRY

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02103426 - An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients | Biotech Hunter | Biotech Hunter